← Leaderboards
Jay Edward Wrobel
Fox Chase Chemical Diversity Center, Inc
$4,494,262
Attributed
$4,494,262
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1000K · FY2015–23$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,494,262 · 5
By mechanism
R44$2,996,138 · 1
R43$900,000 · 3
R41$598,124 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignPharmaceutical ChemistryToxic EffectPre-ClinicalAnalogBaseLeadIn Vitro AssayProteinsPropertyDrug DiscoveryBindingSmall Business Innovation Research GrantNovel StrategiesSmall Business Technology Transfer ResearchFoxesEvaluationIn VitroLead OptimizationIn VivoMouse ModelPharmaceutical PreparationsScientistUniversities
Grant awards (8)
Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens$291,624
R41 · FY2023 · AI · contact PI
Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens$306,500
R41 · FY2022 · AI · contact PI
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT$999,965
R44 · FY2021 · HL · contact PI
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT$996,228
R44 · FY2020 · HL · contact PI
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT$999,945
R44 · FY2019 · HL · contact PI
Soft LXR Agonists for the Treatment of Idiopathic Pulmonary Fibrosis$300,000
R43 · FY2018 · HL · contact PI
INHIBITORS OF THE PHD2 ZINC FINGER TO TREAT ANEMIA$300,000
R43 · FY2017 · HL · contact PI
Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease$300,000
R43 · FY2015 · DK · contact PI